

Contents

Preface *xiii*

1 Exploring Protein–Protein Interactions: Concepts, Methods, and Implications *1*

Mi Zhou and Renxiao Wang

- 1.1 General Concepts of Protein–Protein Interactions *1*
 - 1.1.1 Definition of Protein–Protein Interactions *1*
 - 1.1.2 Structural Properties of Protein–Protein Interactions *2*
 - 1.1.3 Diverse Types of Protein–Protein Interactions *3*
 - 1.1.3.1 Enzyme–Substrate Interactions *3*
 - 1.1.3.2 Receptor–Ligand Interactions *3*
 - 1.1.3.3 Antigen–Antibody Interactions *3*
 - 1.1.3.4 Chaperone–Client Interactions *4*
 - 1.1.3.5 Scaffold Interactions *4*
 - 1.2 Functional Significance of Protein–Protein Interactions *4*
 - 1.2.1 Cellular Signal Transduction *5*
 - 1.2.2 Regulation of Gene Expression *6*
 - 1.2.3 Immune Response *8*
 - 1.2.3.1 Immune Cell Migration *8*
 - 1.2.3.2 T-Cell Antigen Recognition and Activation *8*
 - 1.2.3.3 B-Cell Antigen Recognition and Activation *9*
 - 1.2.4 Protein Degradation Pathway *9*
 - 1.2.5 Disease Mechanisms *10*
 - 1.2.5.1 Cancer *10*
 - 1.2.5.2 Neurodegenerative Diseases *11*
 - 1.2.5.3 Infectious Disease *11*
 - 1.3 Methods for Analyzing Protein–Protein Interactions *12*
 - 1.3.1 Experimental Methods *12*
 - 1.3.1.1 Structure Determination *12*
 - 1.3.1.2 Affinity, Kinetics, and Thermodynamics Measurement *13*
 - 1.3.1.3 Large-Scale PPI Network Mapping *13*
 - 1.3.2 Computational Methods *14*
 - 1.3.2.1 Sequence-Based Methods *14*
 - 1.3.2.2 Structure-Based Methods *15*

1.3.2.3	Network-Based Methods	15
1.4	Implications of the Basic Research on Protein–Protein Interactions	16
1.4.1	Advancing Disease Understanding and Diagnosis	16
1.4.2	Driving Target-Based Drug Discovery	17
1.4.3	Fostering Innovations in Biotechnology	17
1.5	Conclusions and Perspectives	19
	References	19

2 Overview of Drug Discovery Targeting PPI Systems 29

Hao Ma and Jian Zhang

2.1	Introduction	29
2.2	Fundamentals of Protein–Protein Interactions	30
2.2.1	Basic Principles of Protein Structure and Function	30
2.2.2	Types of Protein–Protein Interactions	32
2.2.3	Significance of PPIs in Cellular Processes and Disease Pathways	32
2.3	Challenges in Targeting PPI Systems	33
2.3.1	Structural Complexities of PPI Interfaces	33
2.3.2	Dynamics and Flexibility of Protein Complexes	34
2.3.3	Druggability Issues Associated with PPI Targets	35
2.4	Approaches in Drug Discovery Targeting PPI Systems	35
2.4.1	High-Throughput Drug Design (HTS) Methods	35
2.4.2	Structure-Based Drug Design (SBDD) Techniques	36
2.4.3	Fragment-Based Drug Discovery (FBDD) Strategies	37
2.4.4	Computational Methods for Predicting PPI Inhibitors	38
2.5	Case Studies and Success Stories	40
2.5.1	BCL Family	40
2.5.1.1	Bcl-2	40
2.5.1.2	Bcl-xL	42
2.5.1.3	MCL-1	42
2.5.2	p53–MDM2	43
2.5.3	XIAP/c-IAP1	44
2.5.4	CD40–CD40L	45
2.5.5	Cyclin-Dependent Kinase (CDK)	46
2.5.6	PD-1/PD-L1	47
2.5.7	Hsp90–Cdc37	48
2.5.8	Menin–MLL	48
2.5.9	Kras–SOS1	49
2.5.10	Keap1–Nrf2 PPI	49
2.6	Conclusion	51
	References	53

3 Fluorescence Resonance Energy Transfer Technology and its Applications 61

Jing-Yu Lang

3.1	Introduction	61
3.2	Mechanism of FRET	61
3.3	Applications of FRET	63

3.3.1	Molecular Interactions	63
3.3.2	Conformational Changes	64
3.3.3	Cellular Imaging	64
3.3.4	Drug Discovery	64
3.3.5	Clinical Diagnosis	65
3.3.6	Structural Biology	66
3.3.7	Materials Science	66
3.3.8	Environmental and Agricultural Sciences	66
3.4	Advantages and Limitations	67
3.5	Recent Advances	68
3.6	Conclusion	70
	Acknowledgements	71
	References	71
4	Dissect Protein Interactions Using Mass Spectrometry	75
	<i>Bin Liao and Liang Zhang</i>	
4.1	Introduction	75
4.2	Affinity Purification Coupled with Mass Spectrometry (AP-MS)	76
4.3	Proximity Labeling	81
4.4	Cross-linking Mass Spectrometry (XL-MS)	84
4.5	Co-fractionation Coupled with Mass Spectrometry (CF-MS)	88
4.6	Thermal Proximity Co-aggregation (TPCA)	90
4.7	Limited Proteolysis–Mass Spectrometry (LiP–MS)	93
4.8	Conclusion and Outlook	95
	Acknowledgements	96
	References	96
5	Detection of Protein–Protein Interactions In Situ via Proximity Ligation Assay	105
	<i>Xinyue Zhou and Peng Zou</i>	
5.1	Introduction	105
5.2	Implementations of Proximity Ligation Assay	106
5.3	Applications of PLA for Detecting Protein–Protein Interactions	108
5.4	Conclusions and Outlooks	109
	Acknowledgments	110
	References	110
6	Application of Surface Plasmon Resonance in the Characterization of Protein–Protein Interactions	115
	<i>Yuanyuan Xie and Jianrong Xu</i>	
6.1	Introduction	115
6.1.1	Protein–Protein Interactions	115
6.1.2	Principle of Surface Plasmon Resonance	115
6.1.3	Advantage of SPR	116
6.2	Applications of SPR Assays in PPIs Characterization	117
6.2.1	SPR Application in Binary PPI Systems	117
6.2.1.1	SPR Assay in Verifying and Measuring PPIs	117

6.2.1.2	SPR-Guided Screening and Optimization in Drug Discovery	120
6.2.1.3	SPR in the Validation of PPI Interface	123
6.2.2	SPR Application in Ternary PPI Systems	126
6.2.2.1	SPR-Based Epitope Competition Assays	126
6.2.2.2	SPR-Based Drug Discovery of PPI Modulators	128
6.2.2.3	SPR Applications in Targeted Protein Degradation	130
6.3	Advantages and Limitations of SPR Application for PPIs	131
6.4	Future Directions	132
	References	133

7 **Computational Methods for Protein–Protein Interactions** 139

Hao Li, Yurui Li, and Sheng-You Huang

7.1	Introduction	139
7.2	Protein–Protein Docking	140
7.2.1	Sampling	142
7.2.1.1	Traditional Search Algorithms	142
7.2.1.2	Deep Learning-Based Search Algorithms	144
7.2.2	Scoring	145
7.2.2.1	Traditional Scoring Function	145
7.2.2.2	Deep Learning-Based Scoring Function	146
7.2.3	Template-based Docking	147
7.3	End-to-end Structure Prediction	148
7.4	CAPRI Experiments	151
7.4.1	CASP13-CAPRI	152
7.4.2	CASP14-CAPRI	152
7.4.3	CASP15-CAPRI	153
7.5	Challenges and Future Directions	154
	Acknowledgments	155
	Author Contributions	155
	References	155

8 **Foldamers as Inhibitors of Aberrant Protein–Protein Interactions** 163

Nicholas H. Stillman, Ryan A. Dohoney, Charles Z. Baysah, and Sunil Kumar

8.1	Introduction	163
8.2	The Evolution of Hamilton’s Oligopyridylamides	164
8.3	Limitations of a Tedious Synthetic Route	165
8.4	OPs as Antagonists of Neurodegeneration	166
8.5	OPs Inhibit HIV Infection	168
8.6	OPs Targeting Type II Diabetes	169
8.7	OPs Targeting and Reactivating Mutant Protein in Cancer	171
8.8	Novel Synthesis of OPs and Alzheimer’s Disease	173
8.9	2D-FAST	174
8.10	OQ Foldamers – Structure and Discovery	181
8.11	Synthesis of OQ Foldamers	182

8.12	OQs as Modulators of Type II Diabetes-Related aPPIs	183
8.13	Mechanistic Insights into OQ Manipulation of aPPIs	186
8.14	Chemical Diversity and Structure Modulate Efficacy of OQs	188
8.15	Modulation of Alzheimer's Disease-Related A β	189
8.16	OQs for the Modulation of Synucleinopathies	191
8.17	Epilogue	194
	Acknowledgement	194
	References	195

9 Application of Sulfonyl- γ -AApeptides for PPI Drug

Discovery 205

Jarais Fontaine and Jianfeng Cai

9.1	Introduction	205
9.2	Application of Sulfonyl- γ -AApeptides	206
9.2.1	Modulation of PPIs Involved in Cancer	206
9.2.1.1	Inhibition of β -catenin/B-cell lymphoma 9 PPIs	206
9.2.1.2	p53-MDM2/MDMX PPIs Inhibitor	208
9.2.1.3	HIF-1 α PPI's Inhibitor	209
9.2.2	Anti-Viral	210
9.2.2.1	HIV Fusion Inhibitor	210
9.2.2.2	Pan-Coronavirus Fusion inhibitor	212
9.2.3	A β -Oligomerization Modulation	213
9.2.4	Diabetes Therapeutics	216
9.3	Future Directions/Conclusion	216
	Acknowledgments	217
	References	217

10 Introduction of the Application of Stapled Peptides in Protein-Protein Interactions Drug Discovery and Their Successful Examples 219

Maxwell J. Austin and Danny Hung-Chieh Chou

10.1	Introduction	219
10.1.1	Stapled Peptides as a Solution to PPI Challenges	219
10.1.2	Growing Importance of PPIs in Drug Discovery	220
10.1.3	Early Development and Success of Stapled Peptides	220
10.1.4	Overview of the Chapter	221
10.2	Stapled Peptides: Structure Features and Benefits	221
10.2.1	Importance of α -Helical Structures in PPIs	221
10.2.2	Designing Stapled Peptides: Mechanism of Stapling	221
10.2.3	Additional Stapling Strategies	222
10.2.3.1	Lactamization Between Lysine and Glutamate/Aspartate	222
10.2.3.2	Azide-Alkyne Cycloaddition	223
10.2.3.3	C—H Activation	224
10.2.3.4	Cys—Cys Initiated Stapling Strategy	224
10.2.3.5	Tyrosine Stapling	224
10.2.4	Advantages of Stapled Peptides in Drug Discovery	225

10.2.4.1	Enhanced Proteolytic Stability	225
10.2.4.2	Improved Cell Permeability	226
10.2.4.3	Ability to Target Previously “Undruggable” PPIs	226
10.2.4.4	Specificity and Affinity Considerations	227
10.3	Successful Applications of Stapled Peptides in Drug Discovery	227
10.3.1	Targeting the MDM2–p53 Interaction	227
10.3.2	Targeting BCL-2 Family Proteins	228
10.3.3	Targeting the β -Catenin/TCF Interaction	229
10.3.4	Infectious Diseases	230
10.3.5	Clinical Progress and Future Directions	231
10.4	Challenges and Limitations	232
10.4.1	Manufacturing and Cost Considerations	232
10.4.2	Delivery Issues: Overcoming Biological Barriers	232
10.4.3	Off-Target Effects and Safety Concerns	233
10.4.4	Resistance Mechanisms	233
10.5	Future Directions	234
10.5.1	Expansion into New Disease Areas	234
10.5.2	Integration with Other Therapeutic Modalities	235
10.5.3	Emerging Delivery Technologies	235
10.5.4	Summary	236
	Acknowledgments	237
	References	237
11	Cyclic Peptides for PPI Drug Discovery	243
	<i>Hong-Gang Hu and Xiang Li</i>	
11.1	Introduction	243
11.2	α -Helix Cyclic Peptides (Stapled Peptides)	244
11.2.1	Antitumor Stapled Peptides	245
11.2.2	Antiviral Stapled Peptides	251
11.2.3	Anti-osteoporosis Stapled Peptides	252
11.2.4	Anti-inflammation Stapled Peptides	253
11.2.5	Anti-diabetes Stapled Peptides	253
11.3	β -Hairpin Cyclic Peptides	253
11.4	Macrocyclic Peptides	255
11.5	Summary and Outlook	255
	References	256
12	Small Molecule Inhibitors Targeting Protein–Protein Interactions in the BCL Protein	263
	<i>Wenhua Zhu, Yangbo He, Gang Chen, and Di Zhu</i>	
12.1	Introduction	263
12.2	Inhibitors of BCL-2 Family Antiapoptotic Proteins	264
12.2.1	Members and Structure of BCL-2 Family Proteins	264
12.2.2	Binding Sites and Key Interactions of BCL-2 Family Proteins	266
12.2.3	Antiapoptotic Proteins of the BCL-2 Family and Cancer	267
12.2.4	BCL-2 Family Antiapoptotic Protein Inhibitors	267
12.2.4.1	Selective Bcl-2/Bcl-xL Inhibitors	268

12.2.4.2	Selective Mcl-1 Inhibitor	280
12.2.4.3	Compounds 54-59	292
12.3	Inhibitors of β -catenin/BCL9	300
12.3.1	Physiological Functions of BCL9	300
12.3.2	β -catenin/BCL9 PPI	300
12.3.3	Targeting β -catenin/BCL9 Small Molecule Inhibitors	301
12.3.3.1	Natural Products and Their Derivatives	301
12.3.3.2	Phenyl-piperidine Derivatives	303
12.3.3.3	3-(4-fluorophenyl)- <i>N</i> -phenylbenzamide Derivatives	305
12.3.3.4	Other β -catenin/BCL9 Small Molecule Inhibitors	307
12.4	Targeting BCL-6 Small Molecule Inhibitors	307
12.4.1	Biological Functions of BCL6	307
12.4.2	Structural Characteristics of the BCL6 BTB/POZ Domain	308
12.4.3	BCL6-targeted Diseases	309
12.4.4	BCL6 Inhibitor	310
12.4.4.1	79-6, FX1 and AP-4-287	310
12.4.4.2	BI3812 and TMX-2164	310
12.4.4.3	BCL6-i and Compound 107	316
12.4.4.4	Compounds 109, 111, WK500B, and GSK137	316
12.4.4.5	CCT369347, CCT372064, and OICR12694	317
12.5	BCL-3 Inhibitors	318
12.5.1	Structural Characteristics of BCL-3	318
12.5.2	Biological Functions of BCL-3	318
12.5.3	BCL-3/P50 Inhibitors	320
12.6	BCL-10 Inhibitors	320
12.6.1	Biological Functions of BCL-10	320
12.6.2	Structural Characteristics of BCL-10	321
12.6.3	BCL-10 and Cancer	322
12.7	Summary	322
	References	323
13	Molecular Glues as Activators for PPI	343
	<i>Xiangbing Qi</i>	
13.1	Introduction	343
13.1.1	Significance of PPI in Biology and Disease	343
13.1.2	Opportunities and Challenges for PPI Drug Discovery	344
13.1.3	Four Classes of PPI Modulators	344
13.2	Molecular Glues as Orthosteric PPI Stabilizers/Activators	347
13.2.1	Design Principles of MG	347
13.2.2	Classification of MGs	347
13.2.2.1	MG Degradors (MGDs)	347
13.2.2.2	MG Stabilizers	354
13.2.2.3	MG Inhibitors	357
13.3	Methods for MG Discovery	358
13.3.1	Modifications of E3 Ligands: Discovery of New CRBN Ligands	360
13.3.2	Phenotype-Based Screening	361

13.3.2.1	Scalable Chemical Profiling	361
13.3.2.2	Proteomics-Based Screening	362
13.3.3	Target-Based Screening	363
13.3.3.1	HTS for PPI Stabilizers	363
13.3.3.2	Rational Design: Discovery of KRAS-CYPA Molecular Glue	363
13.4	Conclusions and Outlook	364
	Contributors	364
	References	364
14	Targeting APC–Asef Protein–Protein Interaction for Drug Discovery in Colorectal Cancer Therapy	373
	<i>Jie Zhong and Xiuyan Yang</i>	
14.1	Introduction	373
14.2	Structural Insights into APC–Asef Interaction	375
14.3	Current APC–Asef Inhibitors	376
14.3.1	Peptides	376
14.3.1.1	Minimal Asef Sequence for APC	376
14.3.1.2	MAI-150–Derived Peptidomimetic Inhibitors	377
14.3.1.3	MAI-203 as the First-in-Class Inhibitor of APC–Asef PPI with Anti-CRC Migration Activity	377
14.3.1.4	Intramolecular Hydrogen Bond Strategy Leading to the Best-in-Class Inhibitor MAI-400	379
14.3.1.5	A More Sensitive FP Assay Led to the Discovery of a Highly Efficient and Potent Inhibitor, MAI-516	380
14.3.1.6	Computer-Aided Design of Tripeptide Inhibitors Disrupting APC–Asef Interaction	381
14.3.2	Small Molecule Inhibitors of APC–Asef PPI	381
14.4	A More Sensitive FP Method for Identifying Highly Active APC–Asef Inhibitors	382
14.5	Conclusions and Outlook	383
	References	385
15	Computational Methods Applied to Drug Discovery of Protein–Protein Interaction Systems	389
	<i>Zhiyong Gu and Xi Cheng</i>	
15.1	Introduction	389
15.2	Computational Methods for PPI Prediction	390
15.2.1	PPI Network Mapping	390
15.2.2	Protein Complex Prediction	394
15.2.3	PPI Modulator Discovery	395
15.2.3.1	Small Molecules	397
15.2.3.2	Peptides and Protein Mimics	400
15.2.3.3	Antibodies	401
15.3	Conclusions and Outlook	401
	References	402
	Index	409